Related Experiment Video
Updated: May 10, 2025
07:34
Use of Animal Model of Sepsis to Evaluate Novel Herbal Therapies
Published on: April 11, 2012
19.3K
Bosutinib mitigates inflammation in experimental sepsis
C M C Cunha1,2, V H P Abreu1,2, V Estato1
1Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brazil.
European Journal of Clinical Investigation
|April 28, 2025
Summary
Bosutinib, a Src family tyrosine kinase inhibitor, shows promise in treating sepsis. This study found it reduced inflammation, improved survival, and protected organs in a mouse model of sepsis.
Area of Science:
- Immunology
- Pharmacology
- Critical Care Medicine
Background:
- Sepsis is a global health crisis with high mortality and limited treatments.
- Inflammation, immune cell dysfunction, and organ damage characterize sepsis pathophysiology.
- Src family tyrosine kinases (SFK) are key regulators of immune responses and inflammation.
Purpose of the Study:
- To investigate the therapeutic potential of bosutinib, an SFK inhibitor, for sepsis treatment.
- To evaluate bosutinib's effects on inflammatory responses and organ function in experimental sepsis.
Main Methods:
- Cecal ligation and puncture (CLP) model of sepsis in mice.
- Treatment with bosutinib (3 mg/kg) or vehicle control.
- Assessment of clinical signs, survival, inflammatory markers, cellular infiltration, lung function, and cerebral microcirculation.
Main Results:
- Bosutinib significantly improved survival rates and reduced sepsis severity.
- Treatment decreased pro-inflammatory cytokines, chemokines, and bacterial load.
- Bosutinib mitigated lung injury and improved cerebral microcirculation by enhancing blood flow and reducing leukocyte adhesion.
Conclusions:
- Bosutinib pretreatment effectively attenuated systemic and neurovascular inflammatory responses in experimental sepsis.
- Targeting SFK with bosutinib offers a potential therapeutic strategy for sepsis.
